MX2022000917A - Agonistas de receptores de cx3cr1 bicíclicos. - Google Patents

Agonistas de receptores de cx3cr1 bicíclicos.

Info

Publication number
MX2022000917A
MX2022000917A MX2022000917A MX2022000917A MX2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A
Authority
MX
Mexico
Prior art keywords
cx3cr1
bicyclic
receptor agonists
compounds
cx3cr1 receptor
Prior art date
Application number
MX2022000917A
Other languages
English (en)
Inventor
Paolo Pevarello
Philip Jones
William Ray
Mary Hamby
Yaima Luzardo Lightfoot
Russell Thomas
Chiara Liberati
Domenica Torino
Valentina Cusano
Francesco Piscitelli
Ali Yousif
Silvia Bovolenta
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2022000917A publication Critical patent/MX2022000917A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/32All rings being cycloaliphatic the ring system containing at least eleven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En este documento se dan a conocer novedosos compuestos cicloalca[b]heteroarilo, que tienen propiedades agonistas del receptor CX3CR1/de fractalquina (CX3CR1), composiciones farmacéuticas que comprenden estos compuestos, procesos químicos para preparar estos compuestos, y su uso en el tratamiento o profilaxis de enfermedades asociadas con la actividad del receptor CX3CR1 en animales, en particular en humanos.
MX2022000917A 2019-07-23 2020-07-23 Agonistas de receptores de cx3cr1 bicíclicos. MX2022000917A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877660P 2019-07-23 2019-07-23
PCT/US2020/043258 WO2021016449A1 (en) 2019-07-23 2020-07-23 Bicyclic cx3cr1 receptor agonists

Publications (1)

Publication Number Publication Date
MX2022000917A true MX2022000917A (es) 2022-04-07

Family

ID=74189124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000917A MX2022000917A (es) 2019-07-23 2020-07-23 Agonistas de receptores de cx3cr1 bicíclicos.

Country Status (11)

Country Link
US (3) US11155538B2 (es)
EP (1) EP4003972A4 (es)
JP (1) JP2022541627A (es)
KR (1) KR20220090492A (es)
CN (1) CN114929681B (es)
AU (1) AU2020316080A1 (es)
BR (1) BR112022001184A2 (es)
CA (1) CA3148454A1 (es)
IL (1) IL290024A (es)
MX (1) MX2022000917A (es)
WO (1) WO2021016449A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220090492A (ko) 2019-07-23 2022-06-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 바이시클릭 cx3cr1 수용체 작용제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UY32443A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
US20120015943A1 (en) * 2010-07-19 2012-01-19 Millennium Pharmacuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2648754A4 (en) * 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
CN104744451A (zh) * 2013-12-30 2015-07-01 中国科学院上海药物研究所 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
PL3131890T3 (pl) * 2014-04-17 2019-12-31 Institut Pasteur Korea Związki do leczenia zakażeń wirusowych
WO2018204370A1 (en) * 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
KR20220090492A (ko) 2019-07-23 2022-06-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 바이시클릭 cx3cr1 수용체 작용제

Also Published As

Publication number Publication date
WO2021016449A1 (en) 2021-01-28
AU2020316080A1 (en) 2022-03-03
CN114929681B (zh) 2024-05-14
EP4003972A4 (en) 2023-07-12
JP2022541627A (ja) 2022-09-26
US11155538B2 (en) 2021-10-26
EP4003972A1 (en) 2022-06-01
US11958839B2 (en) 2024-04-16
BR112022001184A2 (pt) 2022-03-15
IL290024A (en) 2022-03-01
US20220259191A1 (en) 2022-08-18
US20210024510A1 (en) 2021-01-28
CA3148454A1 (en) 2021-01-28
KR20220090492A (ko) 2022-06-29
US20240150332A1 (en) 2024-05-09
CN114929681A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2017007976A (es) Compuestos inhibidores de parg.
MX2022004937A (es) Inhibidores de las cinasas raf.
MX2017007478A (es) Compuestos inhibidores.
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MX2023002507A (es) Inhibidores de cd73.
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MY201535A (en) Therapeutic compounds
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
WO2018067520A3 (en) Therapeutic agents and methods:
BR112016030730A8 (pt) composto
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2022005256A (es) Inhibidores de cd73.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
MX2022000917A (es) Agonistas de receptores de cx3cr1 bicíclicos.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
PH12020550594A1 (en) New alcoxyamino derivatives for treating pain and pain related conditions
MX2021004885A (es) Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor.